Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial

- Post-hoc analysis of GENERATION HD1 study data showed tominersen may have potential benefit in a subgroup of patients - Ionis' partner Roche is in early stages of designing trial for younger adult patient population with less disease burden - Partner to participate in series of webinars for scientific and patient communities beginning Jan. 20, 2022 CARLSBAD, Calif., Jan. 18, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's disease (HD). After halting dosing in the Phase 3 GENERATION HD1 study, exploratory post-hoc analyses suggest tominersen may benefit younger adult patients with lower disease burden. These results require confirmation in a randomized, placebo-controlled study.

The release as fetched from its publisher. ionis.com ↗